{
    "body": "Which are the best treatment options to treat Helicobacter pylori?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/23388847", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23021657", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22322786", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22404517", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20485704", 
        "http://www.ncbi.nlm.nih.gov/pubmed/20429828", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19490560"
    ], 
    "ideal_answer": [
        "The best treatment options  for eradication of Helicobacter pylori involve triple or quadruple drugs therapy with different types of antibiotics.\nBismuth may be also an additional option. Proton pump inhibitors are also included in treatment.\nThe more effective drug list includes: amoxicillin, claritromycin, metronidazole rifabutin.\nAlso chitosan microspheres with Eudragit L100 have been tested."
    ], 
    "exact_answer": [
        [
            "amoxicillin"
        ], 
        [
            "metronidazole"
        ], 
        [
            "claritromycin"
        ], 
        [
            "Proton pump inhibithors"
        ], 
        [
            "rifabutin"
        ], 
        [
            "Eudragit L100"
        ]
    ], 
    "type": "list", 
    "id": "518cb5ab310faafe08000008", 
    "snippets": [
        {
            "offsetInBeginSection": 181, 
            "offsetInEndSection": 332, 
            "text": "Triple therapy, which has been the mainstay of treatment in many countries over the last decade, now has suboptimal results in many parts of the world.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388847", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 620, 
            "offsetInEndSection": 782, 
            "text": "equential therapy and quadruple therapy (either bismuth-based or non-bismuth-based) are the best current options to replace initial treatment with triple therapy.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23388847", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 725, 
            "offsetInEndSection": 1080, 
            "text": "olecular tests can be used to detect H. pylori and clarithromycin and/or fluoroquinolone resistance in gastric biopsies without necessitating culture. In regions of high clarithromycin resistance, such as France, sequential treatment or bismuth-containing quadruple therapies are replacing standard triple therapies for the first-line empirical treatment.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23021657", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1366, 
            "offsetInEndSection": 1460, 
            "text": "The evidence in favour of bismuth compounds for treating infected children is still not clear.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22404517", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 323, 
            "offsetInEndSection": 457, 
            "text": "Chitosan microspheres with multiple Eudragit L100 cores were easily prepared by a new emulsification/coagulation encapsulating method.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22322786", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 894, 
            "offsetInEndSection": 1026, 
            "text": "the multi-core chitosan microspheres could serve as a satisfactory vehicle for stomach-specific delivery of hydrophilic antibiotics.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22322786", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 499, 
            "offsetInEndSection": 648, 
            "text": "Treatment consisted of a one-week regimen containing a PPI twice daily, amoxicillin (A) 1 g twice daily and rifabutin (R) 300 mg once daily (PPI-AR).", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20485704", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 829, 
            "offsetInEndSection": 956, 
            "text": "Pretreatment antibiotic susceptibility to metronidazole, clarithromycin and A was evaluated using a validated epsilometer test.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20485704", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 289, 
            "offsetInEndSection": 564, 
            "text": "four different strategies for prevention of rebleeding in patients with peptic ulcer hemorrhage: 1) test for H. pylori and treatment, if positive; 2) proton pump inhibitor maintenance; 3) no preventive treatment; 4) empirical H. pylori eradication immediately after bleeding.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19490560", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 911, 
            "offsetInEndSection": 1225, 
            "text": "Empirical H. pylori eradication was the dominant strategy: its estimated rate of recurrent bleeding was lower (6.1%) than those of strategies 1 (7.4%), 2 (11.1%), and 3 (18.4%) and it was the least expensive strategy. The results remained stable when variables were changed inside a wide range of plausible values.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19490560", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1527, 
            "offsetInEndSection": 1721, 
            "text": "In patients with bleeding peptic ulcer, empirical treatment of H. pylori infection immediately after feeding is restarted is the most cost-effective strategy for preventing recurrent hemorrhage.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19490560", 
            "endSection": "sections.0"
        }
    ]
}